# Cell-based Assays for Antibody-mediated Transplant Rejection

> **NCT03916822** · — · UNKNOWN · sponsor: **Plexision** · enrollment: 30 (estimated)

## Conditions studied

- Antibody-Mediated Graft Rejection

## Interventions

- **DIAGNOSTIC_TEST:** Alloantigen-specific B-cells

## Key facts

- **NCT ID:** NCT03916822
- **Lead sponsor:** Plexision
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-15
- **Primary completion:** 2021-06-14
- **Final completion:** 2021-08-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916822, "Cell-based Assays for Antibody-mediated Transplant Rejection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03916822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*